Skip to main content
Premium Trial:

Request an Annual Quote

Exosome Diagnostics, Life Technologies Ink Agreement for Oncology Dx Program

NEW YORK (GenomeWeb News) – Exosome Diagnostics today said that it has signed an agreement with Life Technologies to use the Applied Biosystems 7500 Fast Dx Real-Time PCR Instrument for its exosome biofluid in vitro diagnostics program.

Exosome will validate the 7500 platform with exosome biofluid RNA isolation kits in clinical trials beginning this year in brain and prostate cancer. Terms of the alliance were not disclosed.

New York-based Exosome is developing urine- and blood-based molecular diagnostic kits for cancer detection and monitoring. It is partnering with manufacturers to provide branded, OEM diagnostic instruments for regulatory approval and use in its CLIA-certified lab, it said.

"Our product development strategy is to match our exosome-based diagnostics technology with the most technically appropriate and widely accepted platforms available," Exosome Diagnostics COO David Okrongly said in a statement. "The ABI 7500 Fast Dx Real-Time PCR Instrument from Life Technologies combines state of the art quantitative PCR technology with broad market and regulatory acceptance, enabling physicians and laboratory customers to efficiently and accurately access diagnostic results."

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.